METHODS AND COMPOSITIONS ASSOCIATED WITH ADMINISTRATION OF AN EXTRACT OF GANODERMA LUCIDUM
    1.
    发明申请
    METHODS AND COMPOSITIONS ASSOCIATED WITH ADMINISTRATION OF AN EXTRACT OF GANODERMA LUCIDUM 审中-公开
    与甘草提取物相关的方法和组合物

    公开(公告)号:WO2006044616A3

    公开(公告)日:2006-08-24

    申请号:PCT/US2005036961

    申请日:2005-10-14

    CPC classification number: A61K36/074

    Abstract: A fucose-containing glycoprotein fraction obtainable from an extract of Ganoderma Lucidum Reishi, compositions comprising the fuconse-containing glycoprotein fraction, a method to mediate immunomodulating events associated with IL-1 gene expression, a method to stimulate the expression of an inflammatory cytokine, a method to modulate protein kinase pathways associated with inflammatory cytokine Interleukin 1, a method to induce a TLR mediated event; a method to modulate differentiation of a mononuclear cell, a method to enhance cytotoxicity of an NK cell against an NK-sensitive tumor cell, a method to activate the expression of cytokines, a method to induce Blimp-1 expression in a mouse splenic B cell or human B cell, human mature splenocytes or dendritic cell, a method to inhibit LPS induced nitric oxide production in macrophages, a method to activate spleen cells proliferation, and a method to modify the proteome of a spleen cell.

    Abstract translation: 从灵芝提取物获得的含岩藻糖的糖蛋白部分,包含含有蛋白质的糖蛋白部分的组合物,介导与IL-1基因表达相关的免疫调节事件的方法,刺激炎性细胞因子的表达的方法 调节与炎症细胞因子相关的蛋白激酶途径白细胞介素1的方法,诱导TLR介导的事件的方法; 调节单核细胞分化的方法,增强NK细胞对NK敏感性肿瘤细胞的细胞毒性的方法,激活细胞因子表达的方法,在小鼠脾B细胞中诱导Blimp-1表达的方法 或人B细胞,人成熟脾细胞或树突状细胞,抑制巨噬细胞中LPS诱导的一氧化氮产生的方法,活化脾细胞增殖的方法以及修饰脾细胞的蛋白质组的方法。

    Chimeric influenza vaccines
    2.
    发明专利

    公开(公告)号:AU2021268212A1

    公开(公告)日:2022-12-08

    申请号:AU2021268212

    申请日:2021-05-07

    Abstract: The present disclosure relates to a chimeric influenza virus hemagglutinin (HA) polypeptide, comprising one or more stem domain sequence, each having at least 60% homology with a stem domain consensus sequence of HI subtype HA (HI HA) and/or H5 subtype HA (H5 HA), fused with one or more globular head domain sequence, each having at least 60% homology with a globular head domain consensus sequence of HI subtype HA (HI HA) or H5 subtype HA (H5 HA).

Patent Agency Ranking